NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Fionda, Cinzia ^a   Soriani, Alessandra ^a   Zingoni, Alessandra ^a   Santoni, Angela ^a   Cippitelli, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; APICIDIN; BORTEZOMIB; DNAX ACCESSORY MOLECULE 1 PROTEIN; DOXORUBICIN; GENOTOXIC AGENT; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HISTONE DEACETYLASE INHIBITOR; LIGAND; MELPHALAN; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEASOME INHIBITOR; PROTEIN; RADICICOL; STAT3 PROTEIN; TANESPIMYCIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; CD226 ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; T LYMPHOCYTE ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DNA DAMAGE; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; REVIEW; TUMOR CELL; UPREGULATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 84934300385     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/178698     Document Type: Review

References (98)

1. G. Trinchieri, "Biology of natural killer cells", Advances in Immunology, vol. 47, pp. 187-376, 1989.
2. L. Moretta, E. Ciccone, M. C. Mingari, R. Biassoni, and A. Moretta, "Human natural killer cells: origin, clonality, specificity, and receptors", Advances in Immunology, vol. 55, pp. 341-380, 1994.
3. M. H. Helfrich, E. Livingston, I. M. Franklin, and R. L. Soutar, "Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance", Blood Reviews, vol. 11, no. 1, pp. 28-38, 1997.
4. R. A. Kyle and S. V. Rajkumar, "Multiple myeloma", Blood, vol. 111, no. 6, pp. 2962-2972, 2008.
5. A. Mahindra, J. Laubach, N. Raje, N. Munshi, P. G. Richardson, and K. Anderson, "Latest advances and current challenges in the treatment of multiple myeloma", Nature Reviews Clinical Oncology, vol. 9, no. 3, pp. 135-143, 2012.
6. B. Mohty, J. El-Cheikh, I. Yakoub-Agha, H. Avet-Loiseau, P. Moreau, and M. Mohty, "Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and retreatment approaches in the era of novel agents", Leukemia, vol. 26, no. 1, pp. 73-85, 2012.
7. H. Ludwig, B. G. M. Durie, P. McCarthy et al., "IMWG consensus on maintenance therapy in multiple myeloma", Blood, vol. 119, no. 13, pp. 3003-3015, 2012.
8. G. Koehne and S. Giralt, "Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care", Current Opinion in Oncology, vol. 24, no. 6, pp. 720-726, 2012.
9. S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., "Improved survival in multiple myeloma and the impact of novel therapies", Blood, vol. 111, no. 5, pp. 2516-2520, 2008.
10. C. Frohn, M. Höppner, P. Schlenke, H. Kirchner, P. Koritke, and J. Luhm, "Anti-myeloma activity of natural killer lymphocytes", British Journal of Haematology, vol. 119, no. 3, pp. 660-664, 2002.
11. T. Hayashi, T. Hideshima, M. Akiyama et al., "Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application", British Journal of Haematology, vol. 128, no. 2, pp. 192-203, 2005.
12. C. Y. Koh, A. Raziuddin, L. A. Welniak, B. R. Blazar, M. Bennett, and W. J. Murphy, "NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution", Biology of Blood and Marrow Transplantation, vol. 8, no. 1, pp. 17-25, 2002.
13. E. Ullrich, M. Bonmort, G. Mignot, G. Kroemer, and L. Zitvogel, "Tumor stress, cell death and the ensuing immune response", Cell Death and Diferentiation, vol. 15, no. 1, pp. 21-28, 2008.
14. L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer, "The anticancer immune response: indispensable for therapeutic success?" The Journal of Clinical Investigation, vol. 118, no. 6, pp. 1991-2001, 2008.
15. E. Carbone, P. Neri, M. Mesuraca et al., "HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells", Blood, vol. 105, no. 1, pp. 251-258, 2005.
16. Y. M. El-Sherbiny, J. L. Meade, T. D. Holmes et al., "The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells", Cancer Research, vol. 67, no. 18, pp. 8444-8449, 2007.
17. M. Jinushi, M. Vanneman, N. C. Munshi et al., "MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma", Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 4, pp. 1285-1290, 2008.
18. S. Girlanda, C. Fortis, D. Belloni et al., "MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes", Cancer Research, vol. 65, no. 16, pp. 7502-7508, 2005.
19. A. Soriani, A. Zingoni, C. Cerboni et al., "ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype", Blood, vol. 113, no. 15, pp. 3503-3511, 2009.
20. S. Gasser, "DNA damage response and development of targeted cancer treatments", Annals of Medicine, vol. 39, no. 6, pp. 457-464, 2007.
21. S. Armeanu, M. Bitzer, U. M. Lauer et al., "Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate", Cancer Research, vol. 65, no. 14, pp. 6321-6329, 2005.
22. C. Fionda, A. Soriani, G. Malgarini, M. L. Iannitto, A. Santoni, and M. Cippitelli, "Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation", Journal of Immunology, vol. 183, no. 7, pp. 4385-4394, 2009.
23. X. Wu, Y. Tao, J. Hou, X. Meng, and J. Shi, "Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma", Neoplasia, vol. 14, no. 12, pp. 1178-1189, 2012.
24. Y. Shiloh, "The ATM-mediated DNA-damage response: taking shape", Trends in Biochemical Sciences, vol. 31, no. 7, pp. 402-410, 2006.
25. I. B. Roninson, "Tumor cell senescence in cancer treatment", Cancer Research, vol. 63, no. 11, pp. 2705-2715, 2003.
26. C. Gourzones-Dmitriev, A. Kassambara, S. Sahota et al., "DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment", Cell Cycle, vol. 12, no. 17, pp. 2760-2773, 2013.
27. W. M. Kuehl and P. L. Bergsagel, "Molecular pathogenesis of multiple myeloma and its premalignant precursor", Journal of Clinical Investigation, vol. 122, no. 10, pp. 3456-3463, 2012.
28. M. A. Dimopoulos, V. L. Souliotis, A. Anagnostopoulos et al., "Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma", Haematologica, vol. 92, no. 11, pp. 1505-1512, 2007.
29. A. Soriani, M. L. Iannitto, B. Ricci et al., "Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1", The Journal of Immunology, vol. 193, no. 2, pp. 950-960, 2014.
30. W.-C. Lin, F.-T. Lin, and J. R. Nevins, "Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation", Genes and Development, vol. 15, no. 14, pp. 1833-1844, 2001.
31. S. Textor, N. Fiegler, A. Arnold, A. Porgador, T. G. Hofmann, and A. Cerwenka, "Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2", Cancer Research, vol. 71, no. 18, pp. 5998-6009, 2011.
32. 53 triggers anticancer innate immune response through induction of ULBP2", Cell Cycle, vol. 10, no. 19, pp. 3346-3358, 2011.
33. S. Panier and D. Durocher, "Regulatory ubiquitylation in response to DNA double-strand breaks", DNA Repair, vol. 8, no. 4, pp. 436-443, 2009.
34. J. R. Morris, "SUMO in the mammalian response to DNA damage", Biochemical Society Transactions, vol. 38, no. 1, pp. 92-97, 2010.
35. J. R. Morris, C. Boutell, M. Keppler et al., "The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress", Nature, vol. 462, no. 7275, pp. 886-890, 2009.
36. Y. Galanty, R. Belotserkovskaya, J. Coates, S. Polo, K. M. Miller, and S. P. Jackson, "Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks", Nature, vol. 462, no. 7275, pp. 935-939, 2009.
37. K. Ramadan and M. Meerang, "Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: new perspectives for anti-cancer therapy", FEBS Letters, vol. 585, no. 18, pp. 2868-2875, 2011.
38. P. G. Richardson and K. C. Anderson, "Bortezomib: a novel therapy approved for multiple myeloma", Clinical Advances in Hematology & Oncology, vol. 1, no. 10, pp. 596-600, 2003.
39. P. G. Richardson, R. Schlossman, C. Mitsiades, T. Hideshima, N. Munshi, and K. Anderson, "Emerging trends in the clinical use of bortezomib in multiple myeloma", Clinical Lymphoma and Myeloma, vol. 6, no. 2, pp. 84-88, 2005.
40. J. F. San Miguel, R. Schlag, N. K. Khuageva et al., "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma", The New England Journal of Medicine, vol. 359, no. 9, pp. 906-917, 2008.
41. L. Neckers and S. P. Ivy, "Heat shock protein 90", Current Opinion in Oncology, vol. 15, no. 6, pp. 419-424, 2003.
42. L. Whitesell and S. L. Lindquist, "HSP90 and the chaperoning of cancer", Nature Reviews Cancer, vol. 5, no. 10, pp. 761-772, 2005.
43. P. Workman, F. Burrows, L. Neckers, and N. Rosen, "Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress", Annals of the New York Academy of Sciences, vol. 1113, pp. 202-216, 2007.
44. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers, "Targeting the dynamic HSP90 complex in cancer", Nature Reviews Cancer, vol. 10, no. 8, pp. 537-549, 2010.
45. M. Chatterjee, S. Jain, T. Stühmer et al., "STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival", Blood, vol. 109, no. 2, pp. 720-728, 2007.
46. C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan et al., "Antimyeloma activity of heat shock protein-90 inhibition", Blood, vol. 107, no. 3, pp. 1092-1100, 2006.
47. J. Duus, H. I. Bahar, G. Venkataraman et al., "Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma", Leukemia and Lymphoma, vol. 47, no. 7, pp. 1369-1378, 2006.
48. J. Patterson, V. J. Palombella, C. Fritz, and E. Normant, "IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells", Cancer Chemotherapy and Pharmacology, vol. 61, no. 6, pp. 923-932, 2008.
49. P. G. Richardson, C. S. Mitsiades, J. P. Laubach, S. Lonial, A. A. Chanan-Khan, and K. C. Anderson, "Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers", British Journal of Haematology, vol. 152, no. 4, pp. 367-379, 2011.
50. J. Zou, Y. Guo, T. Guettouche, D. F. Smith, and R. Voellmy, "Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1", Cell, vol. 94, no. 4, pp. 471-480, 1998.
51. V. Groh, S. Bahram, S. Bauer, A. Herman, M. Beauchamp, and T. Spies, "Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium", Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 22, pp. 12445-12450, 1996.
52. R. J. Kaufman, "Orchestrating the unfolded protein response in health and disease", Journal of Clinical Investigation, vol. 110, no. 10, pp. 1389-1398, 2002.
53. J. W. Brewer and L. M. Hendershot, "Building an antibody factory: a job for the unfolded protein response", Nature Immunology, vol. 6, pp. 23-29, 2005.
54. B. W. Doble and J. R. Woodgett, "GSK-3: tricks of the trade for a multi-tasking kinase", Journal of Cell Science, vol. 116, no. 7, pp. 1175-1186, 2003.
55. L. Kockeritz, B. Doble, S. Patel, and J. R. Woodgett, "Glycogen synthase kinase-3-an overview of an over-achieving protein kinase", Current Drug Targets, vol. 7, no. 11, pp. 1377-1388, 2006.
56. J. Abisheganaden, C. B. E. Chee, and Y. T. Wang, "Use of bilevel positive airway pressure ventilatory support for pathological fail chest complicating multiple myeloma", European Respiratory Journal, vol. 12, no. 1, pp. 238-239, 1998.
57. H. Wang, J. Brown, and M. Martin, "Glycogen synthase kinase 3: a point of convergence for the host inflammatory response", Cytokine, vol. 53, no. 2, pp. 130-140, 2011.
58. J. Luo, "Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy", Cancer Letters, vol. 273, no. 2, pp. 194-200, 2009.
59. Y. Zhou, S. Uddin, T. Zimmerman, J.-A. Kang, J. Ulaszek, and A. Wickrema, "Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3", Leukemia & Lymphoma, vol. 49, no. 10, pp. 1945-1953, 2008.
60. F. Piazza, S. Manni, L. Q. Tubi et al., "Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomibinduced cell death", BMC Cancer, vol. 10, article 526, 2010.
61. W. G. Gunn, U. Krause, N. Lee, and C. A. Gregory, "Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograf model", Blood, vol. 117, no. 5, pp. 1641-1651, 2011.
62. N. I. Herath, N. Rocques, A. Garancher, A. Eychène, and C. Pouponnot, "GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target", Blood Cancer Journal, vol. 4, no. 1, p. e175, 2014.
63. C. Fionda, G. Malgarini, A. Soriani et al., "Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3", The Journal of Immunology, vol. 190, no. 12, pp. 6662-6672, 2013.
64. R. Bedel, A. Tiery-Vuillemin, C. Grandclement et al., "Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells", Cancer Research, vol. 71, no. 5, pp. 1615-1626, 2011.
65. E. Beurel and R. S. Jope, "Differential regulation of STAT family members by glycogen synthase kinase-3", The Journal of Biological Chemistry, vol. 283, no. 32, pp. 21934-21944, 2008.
66. Q. Zhang, H. Y. Wang, M. Marzec, P. N. Raghunath, T. Nagasawa, and M. A. Wasik, "STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes", Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6948-6953, 2005.
67. H. Lee, P. Zhang, A. Herrmann et al., "Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation", Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 20, pp. 7765-7769, 2012.
68. N. Kato, J. Tanaka, J. Sugita et al., "Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells", Leukemia, vol. 21, no. 10, pp. 2103-2108, 2007.
69. A. Poggi, S. Catellani, A. Garuti, I. Pierri, M. Gobbi, and M. R. Zocchi, "Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate", Leukemia, vol. 23, no. 4, pp. 641-648, 2009.
70. S. Diermayr, H. Himmelreich, B. Durovic et al., "NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities", Blood, vol. 111, no. 3, pp. 1428-1436, 2008.
71. K.-F. Tang, C.-X. He, G.-L. Zeng et al., "Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine", Biochemical and Biophysical Research Communications, vol. 370, no. 4, pp. 578-583, 2008.
72. O. Witt, H. E. Deubzer, T. Milde, and I. Oehme, "HDAC family: what are the cancer relevant targets?" Cancer Letters, vol. 277, no. 1, pp. 8-21, 2009.
73. O. Khan and N. B. La Tangue, "HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications", Immunology and Cell Biology, vol. 90, no. 1, pp. 85-94, 2012.
74. T. Ishii, T. Seike, T. Nakashima et al., "Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib", Blood Cancer Journal, vol. 2, no. 4, article e68, 2012.
75. P. G. Richardson, A. A. Chanan-Khan, S. Lonial et al., "Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study", British Journal of Haematology, vol. 153, no. 6, pp. 729-740, 2011.
76. M. Kaiser, B. Lamottke, M. Mieth et al., "Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma", European Journal of Haematology, vol. 84, no. 4, pp. 337-344, 2010.
77. B. Lamottke, M. Kaiser, M. Mieth et al., "The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases", European Journal of Haematology, vol. 88, no. 5, pp. 406-415, 2012.
78. L. Espada, B. Udapudi, P. Podlesniy, I. Fabregat, C. Espinet, and A. Tauler, "Apoptotic action of E2F1 requires glycogen synthase kinase 3-β activity in PC12 cells", Journal of Neurochemistry, vol. 102, no. 6, pp. 2020-2028, 2007.
79. G. García-Alvarez, V. Ventura, O. Ros, R. Aligué, J. Gil, and A. Tauler, "Glycogen synthase kinase-3beta binds to E2F1 and regulates its transcriptional activity", Biochimica et Biophysica Acta, vol. 1773, no. 3, pp. 375-382, 2007.
80. V. Rebmann, P. Schütt, D. Brandhorst et al., "Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients", Clinical Immunology, vol. 123, no. 1, pp. 114-120, 2007.
81. V. Groh, J. Wu, C. Yee, and T. Spies, "Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation", Nature, vol. 419, no. 6908, pp. 734-738, 2002.
82. E. S. Doubrovina, M. M. Doubrovin, E. Vider et al., "Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma", The Journal of Immunology, vol. 171, no. 12, pp. 6891-6899, 2003.
83. K. Kohga, T. Takehara, T. Tatsumi et al., "Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma", Cancer Research, vol. 69, no. 20, pp. 8050-8057, 2009.
84. O. M. Fischer, S. Hart, A. Gschwind, N. Prenzel, and A. Ullrich, "Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor", Molecular and Cellular Biology, vol. 24, no. 12, pp. 5172-5183, 2004.
85. A. M. Vahdat, K. S. Reiners, V. L. Simhadri et al., "TNF-alphaconverting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species", Leukemia, vol. 24, no. 1, pp. 51-57, 2010.
86. J. N. Kyula, S. Van Schaeybroeck, J. Doherty, C. S. Fenning, D. B. Longley, and P. G. Johnston, "Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer", Clinical Cancer Research, vol. 16, no. 13, pp. 3378-3389, 2010.
87. X. Xu, G. S. Rao, V. Groh et al., "Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression", BMC Cancer, vol. 11, article 194, 2011.
88. B. Huang, R. Sikorski, P. Sampath, and S. H. Torne, "Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer", Journal of Immunotherapy, vol. 34, no. 3, pp. 289-296, 2011.
89. K. Yamanegi, J. Yamane, K. Kobayashi et al., "Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells", Oncology Reports, vol. 28, no. 5, pp. 1585-1590, 2012.
90. L. Markasz, G. Stuber, B. Vanherberghen et al., "Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells", Molecular Cancer Therapeutics, vol. 6, no. 2, pp. 644-654, 2007.
91. A. Aoukaty and R. Tan, "Role for glycogen synthase kinase-3 in NK cell cytotoxicity and X-linked lymphoproliferative disease", Journal of Immunology, vol. 174, no. 8, pp. 4551-4558, 2005.
92. D. Gotthardt, E. M. Putz, E. Straka et al., "Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance", Blood, vol. 124, no. 15, pp. 2370-2379, 2014.
93. J. Bae, A. Munshi, C. Li et al., "Heat shock protein 90 is critical for regulation of phenotype and functional activity of human t lymphocytes and nk cells", Journal of Immunology, vol. 190, no. 3, pp. 1360-1371, 2013.
94. L. E. Rossi, D. E. Avila, R. G. Spallanzani et al., "Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression", Journal of Leukocyte Biology, vol. 91, no. 2, pp. 321-331, 2012.
95. H. Ogbomo, M. Michaelis, J. Kreuter, H. W. Doerr, and J. Cinatl Jr., "Histone deacetylase inhibitors suppress natural killer cell cytolytic activity", FEBS Letters, vol. 581, no. 7, pp. 1317-1322, 2007.
96. N. Fiegler, S. Textor, A. Arnold et al., "Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells", Blood, vol. 122, no. 5, pp. 684-693, 2013.
97. X. Wang, A. Ottosson, C. Ji et al., "Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity", Haematologica, vol. 94, no. 4, pp. 470-478, 2009.
98. X. Feng, J. Yan, Y. Wang et al., "The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosisinducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells", Molecular Immunology, vol. 47, no. 14, pp. 2388-2396, 2010.